Antibody drug conjugates, or ADCs, are highly targeted biopharmaceutical drugs that mix monoclonal antibodies that are specific for surface antigens found on certain tumor cells with highly effective anticancer agents that are linked by chemical linkers. In simple terms, antibody-drug conjugates send "deactivated" cytotoxins to cancer cells. Once the cytotoxin gets inside the tumor cell, a process called "internalization," starts that can kill cancer cells again. Because of this, cell death happens quickly. There are thousands of naturally occurring or chemically made cellular toxins, but only a few of them can be used as parts of an antibody-drug complex (ADC). Chemotherapy drugs like doxorubicin and methotrexate were used to make some of the first ADCs.The increasing cases of breast cancer for which antibody drug conjugates are used as a treatment, is expected to drive growth of the market over the forecast period. The emerging prevalence of breast cancer is expected to bolster the growth of global antibody drug conjugates market.
The global Antibody Drug Conjugates Market is anticipated to grow at a CAGR of 14.0% during the period of forecast (2021-2028).
Major Players in the Antibody Drug Conjugates Industry:
1. F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd, commonly known as Roche, is a Swiss multinational healthcare company. It was founded in and headquartered in. It operates in more than 150 countries.
2. Gilead Sciences, Inc
Gilead Sciences, Inc is an American biopharmaceutical company, was founded in 1987 and headquartered in California, United States. It operates in more than 35 countries worldwide. In January 2022, Gilead and Merck will collaborate on clinical trials to evaluate Trodelvy® in combination with KEYTRUDA® in patients with metastatic non-small cell lung cancer in first-line treatment.
3. GlaxoSmithKline Plc
GlaxoSmithKline Plc is a British multinational pharmaceutical and biotechnology company, was founded in 2000 and headquartered in England, U.K. It operates in over 115 countries. In Nov 2022, following the FDA's request, GSK plc began the process of withdrawing Blenrep's US marketing authorization. The DREAMM-3phase III confirmatory study results did not meet FDA Accelerated Approval standards, hence this request was made. Blenrep is a monotherapy for adult RRMM patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug.
4. Takeda Pharmaceutical Company Ltd
Takeda Pharmaceutical Company Ltd was founded in 1781 and headquartered in Tokyo, Japan. It operates in approximately 80 countries. In April 2023, pair of licensing agreements between BioNTech and Takeda demonstrated that antibody-drug conjugates (ADCs) are solidifying their position in the biopharmaceutical arsenal.
5. Astellas Pharma
Astellas Pharma was founded in 1923 and headquartered in Tokyo, Japan. It operates in more than 70 countries. In May 2023, Sony Corporation and Astellas Pharma Inc. announced a collaborative research agreement to develop a novel Antibody-Drug Conjugate (ADC)*1 platform in oncology based on Sony's proprietary polymeric material, "KIRAVIATM*2 Backbone*3." It is anticipated that ADC will selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and decreasing side effects induced by anti-cancer drugs attacking normal cells.
6. Pfizer, Inc
Pfizer, Inc is an American multinational pharmaceutical and biotechnology corporation, founded in 1849. The headquarter is in Williamsburgh, New York. It operates to over 181 countries. With the $43 billion acquisition of Seagen in April 2023, Pfizer places a massive wager on ADCs. Pfizer has increased its exposure to antibody–drug conjugates (ADCs) and its oncology holdings.
7. Seagen, Inc
Seagen, Inc is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. It was founded in 1997 and headquartered in Washington, U.S. It operates in 65 countries.
8. Daiichi Sankyo Company Ltd
Daiichi Sankyo Company Ltd was founded in 2005 and headquartered in Tokyo, Japan. It operates in 12 European countries. In July 2020, AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) entered into a new global development and commercialization agreement for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new cancer treatment.
9. Oxford Biotherapeutics
Oxford Biotherapeutics was founded in 2004 and headquartered in York, United Kingdom. It operates in many countries.
Definition: Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.
